Approximately 40% of women have dense breast tissue, with 10% classified as extremely dense – a normal finding that indicates a higher ratio of fibroglandular tissue to fat. However, dense breast tissue presents two critical clinical challenges: it can mask small cancers on standard mammography and is associated with an increased risk of developing breast cancer. The FDA now requires all women to be informed whether they have dense breasts.
Lyra offers three advanced screening solutions to address this pressing clinical need.